首页> 外文OA文献 >Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

【2h】

Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

机译：用BRAF抑制剂（BRAFi）达拉非尼或vemurafenib治疗超过疾病进展（PD）的BRAF突变型转移性黑色素瘤患者（pts）的临床特征和生存

页面导航

著录项
相似文献
相关主题

著录项

作者
Chan M; Haydu L; Menzies A. M; Azer M; Klein O; Lyle M; Clements A; Guminski A; Kefford R; Long G;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib [J] . AzerM.W.F., MenziesA.M., HayduL.E., Cancer: A Journal of the American Cancer Society . 2014,第4期

机译：达拉非尼治疗的BRAF突变型黑色素瘤向脑转移的患者的反应和进展模式
2. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression [J] . Puzanov Igor, Amaravadi Ravi K., McArthur Grant A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第11期

机译：维拉非尼治疗BRAF（V600E）黑色素瘤患者的长期结果：疾病进展模式和有限进展的临床管理
3. Characteristics of pyrexia in BRAF(V600E/K) metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial [J] . Menzies A. M., Ashworth M. T., Swann S., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第2期

机译：在I / II期临床试验中，达拉非尼和曲美替尼联合治疗的BRAF（V600E / K）转移性黑色素瘤患者发热异常的特征
4. IMPROVING PREDICTION OF SURVIVAL USING CT-BASED TUMOR CHARACTERISTICS IN PATIENTS TREATED FOR METASTATIC NON-SMALL CELL LUNG CANCER [C] . WALKER H. LAND JR., ALAN LITWIN, DAN MARGOLIS, Artificial Neural Networks in Engineering Conference . 2010

机译：基于CT基肿瘤特征改善对转移性非小细胞肺癌的患者的肿瘤特征预测
5. Associating Computed Tomography (CT) Imaging Response Criteria and Texture Analysis Measurements with Survival in Patients with Metastatic Melanoma Treated with Anti-angiogenic Therapy. [D] . Gray, Mark Russell. 2014

机译：将计算机断层扫描（CT）成像反应标准和纹理分析测量值与接受抗血管生成治疗的转移性黑色素瘤患者的生存率相关联。
6. Comparative safety of BRAF and MEK inhibitors (vemurafenib dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma [O] . Ana Cebollero, Teresa Puértolas, Isabel Pajares, -1

机译：BRAF和MEK抑制剂（vemurafenibdabrafenib和曲美替尼）在BRAF突变的转移性黑色素瘤一线治疗中的比较安全性
7. Negative influence of Melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of metastatic melanoma (MM) patients (pts) harboring BRAF mutation and treated with BRAF inhibitors (BRAFi) [O] . M. Guida, S. Strippoli, A. Albano, 2015

机译：黑素旋蛋白-1受体（MC1R）多态性对转移黑素瘤（mm）患者（PTS）患者携带BRAF突变并用BRAF抑制剂治疗（BRAFI）进行临床结果的负影响（BRAFI）

Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

著录项

相似文献

相关主题

期刊订阅